Buy & Sell Schwab US Dividend Equity ETF (SCHD) – Schwab US Dividend Equity ETF Price Today
Key Stats
- -Market Cap
- Broad Market / FactorSector
- -4.61%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 65% Buy | 35% SellTrading Activity
- 23 daysTypical Hold Time
Over the past 52 weeks, Schwab US Dividend Equity ETF has traded between a low of $25.89 and a high of $32.07, highlighting its annual price range. Over the past three months, Schwab US Dividend Equity ETF has recorded a drawdown of -4.61%, reflecting recent price volatility. On average, investors hold Schwab US Dividend Equity ETF for approximately 23 days, indicating typical investor behavior on the platform.
About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Most Recent News
Boston Scientific invests $1.5B for stake in MiRus, targeting advanced aortic stenosis treatment.
Boston Scientific has invested $1.5 billion to acquire about a 34% stake in MiRus, gaining exclusive rights to its investigational transcatheter aortic valve replacement (TAVR) system designed for severe aortic stenosis. The SIEGEL valve features a n...
Elliott sees hidden value in Bio-Rad via $5B Sartorius stake amid share price slump
Activist investor Elliott Investment Management has taken a significant stake in Bio-Rad Laboratories, which develops medical instruments and software. Bio-Rad's founding family retains majority voting control, complicating activist efforts. Elliott ...
Regeneron's melanoma trial fails, stock drops over 10%, investors urged to explore legal options.
Regeneron Pharmaceuticals announced that its Phase 3 melanoma trial combining fianlimab and Libtayo did not meet the primary endpoint against Keytruda, causing the stock to fall more than 10%. Prior optimism from company executives about the trial's ...
